biostudies-literatureJindra PTTHERAKOS, Inc.Children's Leukemia Research AssociationGlaxoSmithKlineNHLBI NIH HHSCaridian BCTCellGenix, GmbHFresenius-Biotech North America, Inc.HistoGenetics, Inc.The Leukemia & Lymphoma SocietyKiadis PharmaSoligenix, Inc.AriadOtsuka America Pharmaceutical, Inc.National Marrow Donor ProgramThe Medical College of WisconsinSwedish Orphan BiovitrumWellpoint, Inc.Millennium: The Takeda Oncology Co.Seattle GeneticsCelgene CorporationTeva Neuroscience, Inc.Gamida Cell Teva Joint Venture Ltd.SanofiBe the Match FoundationMilliman USA, Inc.Optum Healthcare Solutions, Inc.RemedyMDSigma-Tau PharmaceuticalsTarix PharmaceuticalsStemCyte, A Global Cord Blood Therapeutics Co.Stemsoft Software, Inc.Office of Naval ResearchNational Cancer Institute (NCI)Genentech, Inc.Blue Cross and Blue Shield AssociationAmgen, Inc.Osiris Therapeutics, Inc.NCI NIH HHSGenzyme CorporationMiltenyi Biotec, Inc.Allos, Inc.Buchanan Family FoundationMerck & Co, Inc.27-36https://www.ebi.ac.uk/biostudies/studies/S-EPMC4743880biostudies-literatureUnknown22(1)Despite stringent procedures to secure the best HLA matching between donors and recipients, life-threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Studying single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better disease-free survival (P = .029) and overall survival (P = .009) with less tBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAnalysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes.PMC47438805U01HL069294N00014-13-1-0039U10 HL069294U24-CA76518U24 CA076518N00014-12-1-0142U01 HL069294Milford ERicklefs SMSpellman SHaagenson MWang TMcDermott DHAbdi RJindra PTKraft PPorcella SFConway SEAnzick SLfalseAnalysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes.Despite stringent procedures to secure the best HLA matching between donors and recipients, life-threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Studying single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better disease-free survival (P = .029) and overall survival (P = .009) with less t2016-01-01T00:00:00Z2016 Jan2026-05-05T20:17:12.423Z2019-03-27T02:08:35ZS-EPMC47438802634889210.1016/j.bbmt.2015.08.037